R. Saran, B. Robinson, and K. C. Abbott, US Renal Data System 2016 annual data report: epidemiology of kidney disease in the United States, Am J Kidney Dis, vol.69, issue.3, pp.7-8, 2017.

R. Ferguson, C. E. Grim, and T. J. Opgenorth, A familial risk of chronic renal failure among blacks on dialysis?, J Clin Epidemiol, vol.41, pp.1189-1196, 1988.

B. I. Freedman, B. J. Spray, A. B. Tuttle, and V. M. Buckalew, The familial risk of end-stage renal disease in African Americans, Am J Kidney Dis, vol.21, pp.387-393, 1993.

B. J. Spray, N. G. Atassi, A. B. Tuttle, and B. I. Freedman, Familial risk, age at onset, and cause of end-stage renal disease in white Americans, J Am Soc Nephrol, vol.5, pp.1806-1810, 1995.

B. I. Freedman, C. H. Wilson, B. J. Spray, A. B. Tuttle, I. M. Olorenshaw et al., Familial clustering of end-stage renal disease in blacks with lupus nephritis, Am J Kidney Dis, vol.29, pp.729-732, 1997.

B. I. Freedman, J. M. Soucie, S. M. Stone, and S. Pegram, Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy, Am J Kidney Dis, vol.34, pp.254-258, 1999.

B. I. Freedman, S. S. Iskandar, and R. G. Appel, The link between hypertension and nephrosclerosis, Am J Kidney Dis, vol.25, pp.207-221, 1995.
DOI : 10.1016/0272-6386(95)90001-2

B. I. Freedman, C. D. Langefeld, and K. K. Andringa, End-stage renal disease in African Americans with lupus nephritis is associated with APOL1, Arthritis Rheum, vol.66, pp.390-396, 2014.
DOI : 10.1002/art.38220
URL : https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.38220

J. B. Kopp, G. W. Nelson, and K. Sampath, APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy, J Am Soc Nephrol, vol.22, pp.2129-2137, 2011.

G. Genovese, D. J. Friedman, and M. D. Ross, Association of trypanolytic ApoL1 variants with kidney disease in African Americans, Science, vol.329, pp.841-845, 2010.

S. Tzur, S. Rosset, and R. Shemer, Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene, Hum Genet, vol.128, pp.345-350, 2010.

C. P. Larsen, M. L. Beggs, and M. Saeed, Histopathologic findings associated with APOL1 risk variants in chronic kidney disease, Mod Pathol, vol.28, pp.95-102, 2015.
DOI : 10.1038/modpathol.2014.92
URL : https://www.nature.com/articles/modpathol201492.pdf

T. V. Perneger, P. K. Whelton, M. J. Klag, and K. A. Rossiter, Diagnosis of hypertensive end-stage renal disease: effect of patient's race, Am J Epidemiol, vol.141, pp.10-15, 1995.

L. J. Appel, J. T. Wright, and T. Greene, Intensive blood-pressure control in hypertensive chronic kidney disease, N Engl J Med, vol.363, pp.918-929, 2010.

. Sprint-research-group, A randomized trial of intensive versus standard blood-pressure control, N Engl J Med, vol.373, pp.2103-2116, 2015.

J. T. Wright, G. Bakris, and T. Greene, Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial, JAMA, vol.288, pp.2421-2431, 2002.

B. I. Freedman and A. H. Cohen, Hypertension-attributed nephropathy: what's in a name?, Nat Rev Nephrol, vol.12, pp.27-36, 2016.
DOI : 10.1038/nrneph.2015.172

C. P. Larsen, M. L. Beggs, M. Saeed, and P. D. Walker, Apolipoprotein L1 risk variants associate with systemic lupus erythematosusassociated collapsing glomerulopathy, J Am Soc Nephrol, vol.24, pp.722-725, 2013.
DOI : 10.1681/asn.2012121180
URL : http://jasn.asnjournals.org/content/24/5/722.full.pdf

A. E. Ashley-koch, E. C. Okocha, and M. E. Garrett, MYH9 and APOL1 are both associated with sickle cell disease nephropathy, Br J Haematol, vol.155, pp.386-394, 2011.

B. Nichols, P. Jog, and J. H. Lee, Innate immunity pathways regulate the nephropathy gene apolipoprotein L1, Kidney Int, vol.87, pp.332-342, 2015.

A. N. Kasembeli, R. Duarte, and M. Ramsay, APOL1 risk variants are strongly associated with HIV-associated nephropathy in black South Africans, J Am Soc Nephrol, vol.26, pp.2882-2890, 2015.

B. I. Freedman, J. E. Locke, A. M. Reeves-daniel, and B. A. Julian, Apolipoprotein L1 gene effects on kidney transplantation, Semin Nephrol, vol.37, pp.530-537, 2017.

J. B. Kopp, M. W. Smith, and G. W. Nelson, MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis, Nat Genet, vol.40, pp.1175-1184, 2008.

W. H. Kao, M. J. Klag, and L. A. Meoni, MYH9 is associated with nondiabetic end-stage renal disease in African Americans, Nat Genet, vol.40, pp.1185-1192, 2008.

C. Arrondel, N. Vodovar, and B. Knebelmann, Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes, J Am Soc Nephrol, vol.13, pp.65-74, 2002.

G. W. Nelson, B. I. Freedman, and D. W. Bowden, Dense mapping of MYH9 localizes the strongest kidney disease associations to the region of introns 13 to 15, Hum Mol Genet, vol.19, pp.1805-1815, 2010.

T. K. Oleksyk, G. W. Nelson, P. An, J. B. Kopp, and C. A. Winkler, Worldwide distribution of the MYH9 kidney disease susceptibility alleles and haplotypes: evidence of historical selection in Africa, PLoS One, vol.5, p.11474, 2010.

M. E. Grams, C. M. Rebholz, and Y. Chen, APOL1 risk, and eGFR decline in the general population, J Am Soc Nephrol, vol.27, pp.2842-2850, 2016.

A. Parsa, W. H. Kao, and D. Xie, APOL1 risk variants, race, and progression of chronic kidney disease, N Engl J Med, vol.369, pp.2183-2196, 2013.

M. S. Lipkowitz, B. I. Freedman, and C. D. Langefeld, Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans, Kidney Int, vol.83, pp.114-120, 2013.

C. A. Peralta, K. Bibbins-domingo, and E. Vittinghoff, APOL1 genotype and race differences in incident albuminuria and renal function decline, J Am Soc Nephrol, vol.27, pp.887-893, 2016.

S. Limou, G. W. Nelson, J. B. Kopp, and C. A. Winkler, APOL1 kidney risk alleles: population genetics and disease associations, Adv Chronic Kidney Dis, vol.21, pp.426-433, 2014.
DOI : 10.1053/j.ackd.2014.06.005
URL : http://europepmc.org/articles/pmc4157456?pdf=render

A. Cooper, H. Ilboudo, and V. P. Alibu, APOL1 renal risk variants have contrasting resistance and susceptibility associations with African trypanosomiasis, Elife, vol.6, 2017.
DOI : 10.7554/elife.25461
URL : https://doi.org/10.7554/elife.25461

S. Limou, G. W. Nelson, and L. Lecordier, Sequencing rare and common APOL1 coding variants to determine kidney disease risk, Kidney Int, vol.88, pp.754-763, 2015.
DOI : 10.1038/ki.2015.151
URL : http://europepmc.org/articles/pmc4591109?pdf=render

R. Thomson, G. Genovese, and C. Canon, Evolution of the primate trypanolytic factor APOL1, Proc Natl Acad Sci U S A, vol.111, pp.2130-2139, 2014.

M. Samanovic, M. P. Molina-portela, A. D. Chessler, B. A. Burleigh, and J. Raper, Trypanosome lytic factor, an antimicrobial high-density lipoprotein, ameliorates Leishmania infection, PLoS Pathog, vol.5, p.1000276, 2009.

H. E. Taylor, A. K. Khatua, and W. Popik, The innate immune factor apolipoprotein L1 restricts HIV-1 infection, J Virol, vol.88, pp.592-603, 2014.

P. J. Mclaren, A. Gawanbacht, and N. Pyndiah, Identification of potential HIV restriction factors by combining evolutionary genomic signatures with functional analyses, Retrovirology, vol.12, p.41, 2015.

A. Fogo, J. A. Breyer, and M. C. Smith, Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators, Kidney Int, vol.51, pp.244-252, 1997.

M. D. Hughson, W. E. Hoy, and S. A. Mott, APOL1 risk alleles are associated with more severe arteriosclerosis in renal resistance vessels with aging and hypertension, Kidney Int Rep, vol.1, pp.10-23, 2016.

P. Beckerman, J. Bi-karchin, and A. S. Park, Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice, Nat Med, vol.23, pp.429-438, 2017.

J. B. Kopp, C. A. Winkler, and X. Zhao, Clinical features and histology of apolipoprotein L1-associated nephropathy in the FSGS Clinical Trial, J Am Soc Nephrol, vol.26, pp.1443-1448, 2015.

D. M. Fine, W. G. Wasser, and M. M. Estrella, APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease, J Am Soc Nephrol, vol.23, pp.343-350, 2012.

C. P. Larsen, M. L. Beggs, P. D. Walker, M. Saeed, J. M. Ambruzs et al., Histopathologic effect of APOL1 risk alleles in PLA2R-associated membranous glomerulopathy, Am J Kidney Dis, vol.64, pp.161-163, 2014.

A. M. Reeves-daniel, S. S. Iskandar, and D. W. Bowden, Is collapsing C1q nephropathy another MYH9-associated kidney disease? A case report, Am J Kidney Dis, vol.55, pp.21-24, 2010.

B. I. Freedman, C. D. Langefeld, and L. Lu, Differential effects of MYH9 and APOL1 risk variants on FRMD3 association with diabetic ESRD in African Americans, PLoS Genet, vol.7, p.1002150, 2011.

S. M. Madhavan, J. F. O'toole, M. Konieczkowski, S. Ganesan, L. A. Bruggeman et al., APOL1 localization in normal kidney and nondiabetic kidney disease, J Am Soc Nephrol, vol.22, pp.2119-2128, 2011.

L. Ma, G. S. Shelness, and J. A. Snipes, Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell lines, J Am Soc Nephrol, vol.26, pp.339-348, 2015.

A. M. Reeves-daniel, J. A. Depalma, and A. J. Bleyer, The APOL1 gene and allograft survival after kidney transplantation, Am J Transplant, vol.11, pp.1025-1030, 2011.

B. I. Freedman, B. A. Julian, and S. O. Pastan, Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure, Am J Transplant, vol.15, pp.1615-1622, 2015.

B. I. Freedman, S. O. Pastan, and A. K. Israni, APOL1 genotype and kidney transplantation outcomes from deceased African American donors, Transplantation, vol.100, pp.194-202, 2016.
DOI : 10.1097/tp.0000000000000969
URL : http://europepmc.org/articles/pmc4684443?pdf=render

A. Weckerle, J. A. Snipes, and D. Cheng, Characterization of circulating APOL1 protein complexes in African Americans, J Lipid Res, vol.57, pp.120-130, 2016.

B. T. Lee, V. Kumar, and T. A. Williams, The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival, Am J Transplant, vol.12, pp.1924-1928, 2012.

L. A. Bruggeman, J. F. O'toole, and M. D. Ross, Plasma apolipoprotein L1 levels do not correlate with CKD, J Am Soc Nephrol, vol.25, pp.634-644, 2014.

P. D. Dummer, S. Limou, and A. Z. Rosenberg, APOL1 kidney disease risk variants: an evolving landscape, Semin Nephrol, vol.35, pp.222-236, 2015.

O. A. Olabisi, J. Y. Zhang, and L. Verplank, APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases, Proc Natl Acad Sci, vol.113, pp.830-837, 2016.

L. Ma, J. W. Chou, and J. A. Snipes, APOL1 renal-risk variants induce mitochondrial dysfunction, J Am Soc Nephrol, vol.28, pp.1093-1105, 2017.

D. Granado, D. Muller, and V. Krausel, Intracellular APOL1 risk variants cause cytotoxicity accompanied by energy depletion, J Am Soc Nephrol, vol.28, pp.3227-3238, 2017.
DOI : 10.1681/asn.2016111220
URL : https://jasn.asnjournals.org/content/jnephrol/28/11/3227.full.pdf

X. Lan, A. Jhaveri, and K. Cheng, APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability, Am J Physiol Renal Physiol, vol.307, pp.326-336, 2014.
DOI : 10.1152/ajprenal.00647.2013
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121568/pdf

D. Cheng, A. Weckerle, and Y. Yu, Biogenesis and cytotoxicity of APOL1 renal risk variant proteins in hepatocytes and hepatoma cells, J Lipid Res, vol.56, pp.1583-1593, 2015.

S. S. Hayek, K. H. Koh, and M. E. Grams, A tripartite complex of suPAR, APOL1 risk variants and alphavbeta3 integrin on podocytes mediates chronic kidney disease, Nat Med, vol.23, pp.945-953, 2017.

B. A. Julian, R. S. Gaston, and W. M. Brown, Effect of replacing race with apolipoprotein L1 genotype in calculation of Kidney Donor Risk Index, Am J Transplant, vol.17, pp.1540-1548, 2017.

A. Ojo and G. A. Knoll, APOL1 genotyping of African American deceased organ donors: not just yet, Am J Transplant, vol.15, pp.1457-1458, 2015.

K. A. Newell, R. N. Formica, and J. S. Gill, Integrating APOL1 gene variants into renal transplantation: considerations arising from the American Society of Transplantation Expert Conference, Am J Transplant, vol.17, pp.901-911, 2017.

M. E. Grams, Y. Sang, and A. S. Levey, Kidney-failure risk projection for the living kidney-donor candidate, N Engl J Med, vol.374, pp.411-421, 2016.

T. Kofman, V. Audard, and C. Narjoz, APOL1 polymorphisms and development of CKD in an identical twin donor and recipient pair, Am J Kidney Dis, vol.63, pp.816-819, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-01002129

N. A. Zwang, A. Shetty, and N. Sustento-reodica, APOL1-associated end-stage renal disease in a living kidney transplant donor, Am J Transplant, vol.16, pp.3568-3572, 2016.

P. B. Shah, J. E. Cooper, M. S. Lucia, C. Boils, C. P. Larsen et al., APOL1 polymorphisms in a deceased donor and early presentation of collapsing glomerulopathy and focal segmental glomerulosclerosis in two recipients, Am J Transplant, vol.16, pp.1923-1927, 2016.

J. E. Locke, D. Sawinski, and R. D. Reed, Apolipoprotein L1 and chronic kidney disease risk in young potential living kidney donors, Ann Surg, vol.267, pp.1161-1168, 2018.

D. M. Cohen, A. Mittalhenkle, D. L. Scott, C. J. Young, and D. J. Norman, African American living-kidney donors should be screened for APOL1 risk alleles, Transplantation, vol.92, pp.722-725, 2011.

B. I. Freedman and B. A. Julian, Should kidney donors be genotyped for APOL1 risk alleles?, Kidney Int, vol.87, pp.671-673, 2015.

G. N. Nadkarni, C. M. Wyatt, B. Murphy, and M. J. Ross, APOL1: a case in point for replacing race with genetics, Kidney Int, vol.91, pp.768-770, 2017.

C. L. Nicholas, C. P. Larsen, and H. Liapis, Collapsing glomerulopathy: a 30-year perspective and single, large center experience, Clin Kidney J, vol.10, pp.443-449, 2017.

M. P. Molina-portela, M. Samanovic, and J. Raper, Distinct roles of apolipoprotein components within the trypanosome lytic factor complex revealed in a novel transgenic mouse model, J Exp Med, vol.205, pp.1721-1728, 2008.

L. Lecordier, B. Vanhollebeke, and P. Poelvoorde, C-Terminal mutants of apolipoprotein L-I efficiently kill both Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense, PLoS Pathog, vol.5, p.1000685, 2009.

L. A. Bruggeman, Z. Wu, and L. Luo, APOL1-G0 or APOL1-G2 transgenic models develop preeclampsia but not kidney disease, J Am Soc Nephrol, vol.27, pp.3600-3610, 2016.
DOI : 10.1681/asn.2015111220
URL : https://jasn.asnjournals.org/content/27/12/3600.full.pdf

B. R. Anderson, D. N. Howell, and K. Soldano, In vivo modeling implicates APOL1 in nephropathy: evidence for dominant negative effects and epistasis under anemic stress, PLoS Genet, vol.11, p.1005349, 2015.

A. M. Kotb, O. Simon, and A. Blumenthal, Knockdown of ApoL1 in zebrafish larvae affects the glomerular filtration barrier and the expression of nephrin, PLoS One, vol.11, p.153768, 2016.

Y. Fu, J. Y. Zhu, and A. Richman, APOL1-G1 in nephrocytes induces hypertrophy and accelerates cell death, J Am Soc Nephrol, vol.28, pp.1106-1116, 2017.

E. Kruzel-davila, R. Shemer, and A. Ofir, APOL1-mediated cell injury involves disruption of conserved trafficking processes, J Am Soc Nephrol, vol.28, pp.1117-1130, 2017.

, Human African trypanosomiasis, 2014.